Literature DB >> 2524024

A mechanism of c-raf-1 activation: fusion of the lipocortin II amino-terminal sequence with the c-raf-1 kinase domain.

F Mitsunobu1, M Fukui, T Oda, T Yamamoto, K Toyoshima.   

Abstract

In order to understand the mechanism of oncogenic activation, we have analyzed the c-raf-1 gene from the GL-5-JCK human glioblastoma, which underwent rearrangement during transfection experiments. Nucleotide sequencing of cDNA clones derived from the 2.5 kb raf-mRNA, which is a major transcript of raf in NIH3T3 cells transformed with GL-5-JCK DNA, revealed that this mRNA contains sequences derived from the human c-raf-1 gene and the human lipocortin II gene. Translation of the 2.5 kb raf-mRNA predicted a fusion protein consisting of 16 amino-terminal amino acid residues of the lipocortin II and 370 carboxy-terminal amino acid residues of the c-raf-1 protein which contains the kinase domain. Expression of the lipocortin II-raf cDNA using the murine sarcoma virus long terminal repeat as promoter resulted in the transformation of NIH3T3 cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524024

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

1.  Autoregulation of the Raf-1 serine/threonine kinase.

Authors:  R E Cutler; R M Stephens; M R Saracino; D K Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

2.  Human c-fgr induces a monocyte-specific enzyme in NIH 3T3 cells.

Authors:  K Inoue; B Wongsasant; T Akiyama; K Toyoshima
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

3.  Identification of a novel interleukin-6 response element containing an Ets-binding site and a CRE-like site in the junB promoter.

Authors:  K Nakajima; T Kusafuka; T Takeda; Y Fujitani; K Nakae; T Hirano
Journal:  Mol Cell Biol       Date:  1993-05       Impact factor: 4.272

4.  The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase.

Authors:  G H Baeg; A Matsumine; T Kuroda; R N Bhattacharjee; I Miyashiro; K Toyoshima; T Akiyama
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.